ResearcherKagawa UniversityActive in the last 2 years
Minoru Oshima
Matched on ORCID iD 0000-0002-9114-7985; OpenAlex author ID A5042954174, A5044938272, A5112624992. Sources: OpenAlex.
Their work
- Papers
- 25 (first author 7, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 48
2013: 1 paper · 2014: none · 2015: 1 paper · 2016: none · 2017: 2 papers · 2018: 1 paper · 2019: 1 paper · 2020: 2 papers · 2021: 1 paper · 2022: 4 papers · 2023: 2 papers · 2024: 6 papers · 2025: none · 2026: 4 papers
Papers 25
- Preoperative Prediction of Pathologic Response After Neoadjuvant Chemoradiotherapy for Pancreatic Ductal Adenocarcinoma: A Metabolic Response-Based Predictive … Co-author DOI 10.1002/jso.70360↗
- International multicenter validation of an 18F-fluorodeoxyglucose positron emission tomography/computed tomography maximum standardized uptake value 4.0 thresh… Co-author DOI 10.1016/j.surg.2026.110503↗
- A Phase II Study of Short-Course Neoadjuvant Chemoradiotherapy with Gemcitabine, S-1, and Hypofractionated Radiotherapy for Resectable and Borderline Resectabl… First author DOI 10.1245/s10434-025-18714-7↗
- ASO Visual Abstract: A Phase II Study of Short-Course Neoadjuvant Chemoradiotherapy with Gemcitabine, S-1, and Hypofractionated Radiotherapy for Resectable and… First author DOI 10.1245/s10434-025-18894-2↗
- Predictive role of the prognostic nutritional index in patients with pancreatic ductal adenocarcinoma who underwent neoadjuvant chemoradiotherapy followed by c… Co-author DOI 10.1002/jhbp.1424↗
- Tumor location, clinicopathological features, and perioperative and prognostic outcomes in patients who underwent pancreatic resection following neoadjuvant ch… Co-author DOI 10.1016/j.pan.2024.02.007↗
- Relationships between postoperative recurrences and standardized uptake value on 18F-fluorodeoxyglucose-positron emission tomography in patients with resectabl… Co-author DOI 10.1016/j.pan.2024.08.010↗
- Serum Carbohydrate Antigen 19-9 and Metabolite Hypotaurine Are Predictive Markers for Early Recurrence of Pancreatic Ductal Adenocarcinoma. First author DOI 10.1097/mpa.0000000000002304↗
- Prognostic Significance of 18F-FDG PET/CT and Tumor Metabolic Changes in Patients With Pancreatic Ductal Adenocarcinoma. First author DOI 10.21873/anticanres.17151↗
- Short- and Long-Term Outcomes of Neoadjuvant Chemoradiotherapy Followed by Pancreatoduodenectomy in Elderly Patients with Resectable and Borderline Resectable … Co-author DOI 10.3390/jcm13051216↗
- P53 immunolabeling in EUS-FNA biopsy can predict low resection rate and early recurrence in resectable or borderline resectable pancreatic cancer treated with … Co-author DOI 10.1002/jhbp.1286↗
- Efficacy of neoadjuvant chemoradiotherapy followed by pancreatic resection for older patients with resectable and borderline resectable pancreatic ductal adeno… First author DOI 10.1016/j.hpb.2022.10.004↗
- Prediction of local tumor control and recurrence-free survival in patients with pancreatic cancer undergoing curative resection after neoadjuvant chemoradiothe… Co-author DOI 10.1002/jso.26854↗
- Tumor metabolic alterations after neoadjuvant chemoradiotherapy predict postoperative recurrence in patients with pancreatic cancer. Co-author DOI 10.1093/jjco/hyac074↗
- Efficacy and Safety of Neoadjuvant Chemoradiation Therapy Administered for 5 Versus 2 Weeks for Resectable and Borderline Resectable Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000002011↗
- Role of Short-Term Neoadjuvant Chemoradiotherapy for Potentially Resectable Pancreatic Cancer. Co-author DOI 10.1177/0003134821998671↗
- Adequate tissue sampling for the assessment of pathological tumor regression in pancreatic cancer. First author DOI 10.1038/s41598-021-86152-y↗
- Changes and prognostic impact of inflammatory nutritional factors during neoadjuvant chemoradiotherapy for patients with resectable and borderline resectable p… Co-author DOI 10.1186/s12876-020-01566-8↗
- Is surgery after neoadjuvant chemoradiotherapy feasible for elderly patients with resectable or borderline resectable pancreatic ductal adenocarcinoma? Co-author DOI 10.21203/rs.2.21112/v1↗
- The predictors and patterns of the early recurrence of pancreatic ductal adenocarcinoma after pancreatectomy: the influence of pre- and post- operative adjuvan… Co-author DOI 10.1186/s12893-019-0644-z↗
- 18F-fluorodeoxyglucose positron emission tomography to indicate conversion surgery in patients with initially unresectable locally advanced pancreatic cancer. Co-author DOI 10.1093/jjco/hyy033↗
- Personalized Management of Pancreatic Ductal Adenocarcinoma Patients through Computational Modeling. Co-author DOI 10.1158/0008-5472.can-16-1208↗
- A Prospective Phase II Trial of Neoadjuvant S-1 with Concurrent Hypofractionated Radiotherapy in Patients with Resectable and Borderline Resectable Pancreatic … Co-author DOI 10.1245/s10434-017-5921-4↗
- [PET imaging in the diagnosis of pancreatic cancer]. First author PMID 25856989↗
- Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic… Co-author DOI 10.1097/sla.0b013e3182827a65↗
Closest collaborators
The 25 strongest of 48 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Keiichi Okano · 24 shared papers, 2013–2026 · strength 3.74
- Paper Preoperative Prediction of Pathologic Response After Neoadjuvant Chemoradiotherapy for Pancreatic Ductal Adenocarcinoma… DOI 10.1002/jso.70360↗
- Paper A Phase II Study of Short-Course Neoadjuvant Chemoradiotherapy with Gemcitabine, S-1, and Hypofractionated Radiotherapy… DOI 10.1245/s10434-025-18714-7↗
- Paper ASO Visual Abstract: A Phase II Study of Short-Course Neoadjuvant Chemoradiotherapy with Gemcitabine, S-1, and Hypofrac… DOI 10.1245/s10434-025-18894-2↗
- Hironobu Suto · 20 shared papers, 2017–2026 · strength 3.32
- Paper Preoperative Prediction of Pathologic Response After Neoadjuvant Chemoradiotherapy for Pancreatic Ductal Adenocarcinoma… DOI 10.1002/jso.70360↗
- Paper A Phase II Study of Short-Course Neoadjuvant Chemoradiotherapy with Gemcitabine, S-1, and Hypofractionated Radiotherapy… DOI 10.1245/s10434-025-18714-7↗
- Paper ASO Visual Abstract: A Phase II Study of Short-Course Neoadjuvant Chemoradiotherapy with Gemcitabine, S-1, and Hypofrac… DOI 10.1245/s10434-025-18894-2↗
- Toru Shibata · 11 shared papers, 2017–2026 · strength 1.74
- Paper A Phase II Study of Short-Course Neoadjuvant Chemoradiotherapy with Gemcitabine, S-1, and Hypofractionated Radiotherapy… DOI 10.1245/s10434-025-18714-7↗
- Paper ASO Visual Abstract: A Phase II Study of Short-Course Neoadjuvant Chemoradiotherapy with Gemcitabine, S-1, and Hypofrac… DOI 10.1245/s10434-025-18894-2↗
- Paper Relationships between postoperative recurrences and standardized uptake value on 18F-fluorodeoxyglucose-positron emissi… DOI 10.1016/j.pan.2024.08.010↗
- Tsutomu Masaki · 12 shared papers, 2017–2024 · strength 1.54
- Paper P53 immunolabeling in EUS-FNA biopsy can predict low resection rate and early recurrence in resectable or borderline re… DOI 10.1002/jhbp.1286↗
- Paper Serum Carbohydrate Antigen 19-9 and Metabolite Hypotaurine Are Predictive Markers for Early Recurrence of Pancreatic Du… DOI 10.1097/mpa.0000000000002304↗
- Paper Efficacy of neoadjuvant chemoradiotherapy followed by pancreatic resection for older patients with resectable and borde… DOI 10.1016/j.hpb.2022.10.004↗
- Yasuyuki Suzuki · 13 shared papers, 2013–2023 · strength 1.52
- Paper P53 immunolabeling in EUS-FNA biopsy can predict low resection rate and early recurrence in resectable or borderline re… DOI 10.1002/jhbp.1286↗
- Paper Efficacy of neoadjuvant chemoradiotherapy followed by pancreatic resection for older patients with resectable and borde… DOI 10.1016/j.hpb.2022.10.004↗
- Paper Role of Short-Term Neoadjuvant Chemoradiotherapy for Potentially Resectable Pancreatic Cancer. DOI 10.1177/0003134821998671↗
- Mina Nagao · 8 shared papers, 2018–2024 · strength 1.32
- Paper Predictive role of the prognostic nutritional index in patients with pancreatic ductal adenocarcinoma who underwent neo… DOI 10.1002/jhbp.1424↗
- Paper Tumor location, clinicopathological features, and perioperative and prognostic outcomes in patients who underwent pancr… DOI 10.1016/j.pan.2024.02.007↗
- Paper Relationships between postoperative recurrences and standardized uptake value on 18F-fluorodeoxyglucose-positron emissi… DOI 10.1016/j.pan.2024.08.010↗
- Shigeo Takahashi · 8 shared papers, 2017–2024 · strength 1.10
- Paper Relationships between postoperative recurrences and standardized uptake value on 18F-fluorodeoxyglucose-positron emissi… DOI 10.1016/j.pan.2024.08.010↗
- Paper Short- and Long-Term Outcomes of Neoadjuvant Chemoradiotherapy Followed by Pancreatoduodenectomy in Elderly Patients wi… DOI 10.3390/jcm13051216↗
- Paper Efficacy of neoadjuvant chemoradiotherapy followed by pancreatic resection for older patients with resectable and borde… DOI 10.1016/j.hpb.2022.10.004↗
- Akihito Tsuji · 4 shared papers, 2018–2026 · strength 0.76
- Paper A Phase II Study of Short-Course Neoadjuvant Chemoradiotherapy with Gemcitabine, S-1, and Hypofractionated Radiotherapy… DOI 10.1245/s10434-025-18714-7↗
- Paper ASO Visual Abstract: A Phase II Study of Short-Course Neoadjuvant Chemoradiotherapy with Gemcitabine, S-1, and Hypofrac… DOI 10.1245/s10434-025-18894-2↗
- Paper Efficacy and Safety of Neoadjuvant Chemoradiation Therapy Administered for 5 Versus 2 Weeks for Resectable and Borderli… DOI 10.1097/mpa.0000000000002011↗
- Ayaka Shimomura · 3 shared papers, 2022–2024 · strength 0.47
- Paper Prognostic Significance of 18F-FDG PET/CT and Tumor Metabolic Changes in Patients With Pancreatic Ductal Adenocarcinoma. DOI 10.21873/anticanres.17151↗
- Paper Serum Carbohydrate Antigen 19-9 and Metabolite Hypotaurine Are Predictive Markers for Early Recurrence of Pancreatic Du… DOI 10.1097/mpa.0000000000002304↗
- Paper Tumor metabolic alterations after neoadjuvant chemoradiotherapy predict postoperative recurrence in patients with pancr… DOI 10.1093/jjco/hyac074↗
- Yukiko Wada · 2 shared papers, 2022–2024 · strength 0.29
- Paper Serum Carbohydrate Antigen 19-9 and Metabolite Hypotaurine Are Predictive Markers for Early Recurrence of Pancreatic Du… DOI 10.1097/mpa.0000000000002304↗
- Paper Tumor metabolic alterations after neoadjuvant chemoradiotherapy predict postoperative recurrence in patients with pancr… DOI 10.1093/jjco/hyac074↗
- Isamu Makino · 1 shared paper, 2026 · strength 0.19
- Atsushi Tomioka · 1 shared paper, 2026 · strength 0.19
- Teiichi Sugiura · 1 shared paper, 2026 · strength 0.19
- Shintaro Yagi · 1 shared paper, 2026 · strength 0.19
- Yoo‐Seok Yoon · 1 shared paper, 2026 · strength 0.19
- Tetsuya Idichi · 1 shared paper, 2026 · strength 0.19
- Kousei Ishigami · 1 shared paper, 2026 · strength 0.19
- Hongbeom Kim · 1 shared paper, 2026 · strength 0.19
- Hyung Il Seo · 1 shared paper, 2026 · strength 0.19
- Shigeru Marubashi · 1 shared paper, 2026 · strength 0.19
- Naru Kim · 1 shared paper, 2026 · strength 0.19
- Munseok Choi · 1 shared paper, 2026 · strength 0.19
- Masayuki Tanaka · 1 shared paper, 2026 · strength 0.19
- Katsuhisa Ohgi · 1 shared paper, 2026 · strength 0.19
- Yoon Soo Chae · 1 shared paper, 2026 · strength 0.19
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.